Immutep Ltd has released a press release.
Positive Final Data in 2nd Line Metastatic NSCLC Patients
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Immutep
- Expansion of INSIGHT-003 trial for Efti in 1st Line NSCLC
- Initiation of Ph 2/3 Trial for Metastatic Breast Cancer
- Enrolment Target Reached for INSIGHT-003 Trial in NSCLC
- TACTI-003 trial 50% enrolment milestone has been achieved
- Update on MBC trial design following successful FDA meeting
Later from Immutep
- Initiation of Phase 2 Trial for Efti in Soft Tissue Sarcoma
- Response to ASX Aware Query
- Immutep to announce new TACTI-002 data at ASCO 2023
- Approval to start Efti & Bavencio trial in urothelial cancer
- FDA supportive of Efti registrational trial in lung cancer
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep